← all drugs
Gemcitabine Hydrochloride Injection
being discontinued · Oncology · Snapshot: 2026-08-25
- Manufacturers listed
- Hospira, Inc., a Pfizer Company
- Machine-readable
- JSON for this drug
Presentations (3)
| Presentation | Company | Availability | Updated |
|---|---|---|---|
| Gemcitabine Hydrochloride, Injection, 1 g/26.3 mL (38 mg/mL), sterile solution in a single-dose glass vial NovaPlus (NDC 0409-0181-25) | Hospira, Inc., a Pfizer Company | unknown | 09/11/2025 |
| Gemcitabine Hydrochloride, Injection, 200 mg/5.26 mL (38 mg/mL), sterile solution in a single-dose glass vial NovaPlus (NDC 0409-0183-25) | Hospira, Inc., a Pfizer Company | unknown | 09/11/2025 |
| Gemcitabine Hydrochloride, Injection, 2 g/52.6 mL (38 mg/mL), sterile solution in a single-dose glass vial NovaPlus (NDC 0409-0182-25) | Hospira, Inc., a Pfizer Company | unknown | 09/11/2025 |
History
Daily change tracking began 2026-08-25 (index founding). Status flips and availability changes will accumulate here.
Not medical advice. ShortSupply republishes the FDA's drug-shortage data with history added. Talk to your pharmacist or prescriber about your situation — never change medication based on this site.